Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

COVID-19 Clinical Trial

— COVID-Lambda  

Official title:

A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04331899
• Other study ID #: 55619
• Status: Completed
• Phase: Phase 2
• Start date: April 25, 2020
• Est. completion date: May 6, 2021

Study information

• Verified date: November 2021
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.

Description:

Patients will attend up to 9 study visits over a period of up to 28 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: May 6, 2021
• Est. primary completion date: August 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age = 18 years and = 75 years at the time of the assessment

2. Able and willing to understand the study, adhere to all study procedures, and provide written informed consent

3. Diagnosis of COVID-19 disease:

1. If symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 within 72 hours from swab to the time of commencing informed consent:

2. If asymptomatic, initial diagnosis of SARS-CoV-2 infection with positive FDA-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent

Exclusion Criteria:

1. Patients who are hospitalized for inpatient treatment or currently being evaluated for potential hospitalization at the time of initiation of informed consent

2. Patients with a known allergy to Peginterferon Lambda-1a or any component thereof

3. Display symptoms of respiratory distress (Respiratory rate >20, room air oxygen saturation of <94%.)

4. Participation in a clinical trial with or use of any investigational agent within 30 days before screening

5. Treatment with interferons (IFN) within 12 months before screening

6. Previous use of Peginterferon Lambda-1a

7. History or evidence of any intolerance or hypersensitivity to IFNs or other substances contained in the study medication.

8. Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant.

9. Current or previous history of decompensated liver disease (Child-Pugh Class B or C) or hepatocellular carcinoma

10. Co-infected with human immunodeficiency virus (HIV)

11. Significant abnormal laboratory test results at screening.

12. Other significant medical condition that may require intervention during the study

13. Concurrent use of any of the following medications:

1. Therapy with an immunomodulatory agent

2. Current use of heparin or Coumadin

3. Received blood products within 30 days before study randomization

4. Use of hematologic growth factors within 30 days before study randomization

5. Systemic antibiotics, antifungals, or antivirals for treatment of active infection within 24 hours before study randomization

6. Any prescription or herbal product that is not approved by the investigator

7. Long-term treatment (> 2 weeks) with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor

8. Receipt of systemic immunosuppressive therapy within 3 months before screening

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Peginterferon Lambda-1a
Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care

Other:
• Placebo
Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, Purington N, Kamble S, de Vries CR, Quintero O, Feng K, Ley C, Winslow D, Newberry J, Edwards K, Hislop C, Choong I, Maldonado Y, Glenn J, Bhatt A, Blish C, Wang T, Khosla C, — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration Until Viral Shedding Cessation	Time to first of two consecutive negative respiratory secretions obtained by oropharyngeal and/or anterior nare swabs for SARS-CoV-2 by qRT-PCR.	Assessed for up to 28 days
Secondary	Change in Sars-CoV-2 Viral Load	Log10 Oropharyngeal viral load over time, mean change at day 14 (SD). Sars-CoV-2 RNA level in oropharyngeal and/or anterior nare swabs collected daily.	baseline, day 14
Secondary	Area Under the Curve of SARS-COV-2 Viral Load	Log10 viral load area under the curve through day 14, median (IQR). Area under the curve of SARS-CoV-2 viral load in oropharyngeal and/or anterior nare swabs collected daily.	baseline through day 14
Secondary	Duration Until Resolution of Symptoms	Duration until resolution of symptoms in days, median (95% CI). Time to alleviation of all symptoms (fever, chills, cough, nasal congestion, muscle pains), defined as the time from initiation of treatment until all symptoms are rated as absent or mild in symptomatic patients.	Up to 28 days
Secondary	Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment		28 days